Rockwell Medical Technologies, Inc. (RMTI)

[Minding]

From the CC:

I'd like to make an important point regarding the Triferic commercial launch, and that is that we know the renal market extremely well. We have been successful in this market launching, selling and delivering products for 20 years. We understand the customer base. We know we need only a handful of salespeople. There are 9 customers that we need to negotiate with who control about 85% of the market, and we have relationships with them that have been built and maintained over 20 years. Negotiations with these customers are being handled directly by senior management. I can tell you that the interest from renal providers in gaining access to Triferic is very strong. As we've stated in the past, this is not a typical drug launch that involves trying to convince individual doctors to write weekly prescriptions. Triferic is part of the bundled reimbursement. Therefore, it is already accounted for in the bundled payment and, as you know, its reimbursement code became effective July 1 this year. As dialysis providers conclude their pilot programs, we anticipate broad adoption over a short period of time.

Kind regards,
Minding